Insider Trading Alert - Torchmark Corporation And 4 Others Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 3, 2013, 116 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $30.21 to $14,999,997.60.

Highlighted Stocks Traded by Insiders:

Torchmark Corporation (TMK) - FREE Research Report

Stone Spencer H who is Controller at Torchmark Corporation sold 800 shares at $71.63 on Oct. 3, 2013. Following this transaction, the Controller owned 25,499 shares meaning that the stake was reduced by 3.04% with the 800 share transaction.

The shares most recently traded at $71.71, up $0.08, or 0.11% since the insider transaction. Historical insider transactions for Torchmark Corporation go as follows:

  • 4-Week # shares sold: 27
  • 12-Week # shares sold: 1,930
  • 24-Week # shares sold: 2,730

The average volume for Torchmark Corporation has been 374,700 shares per day over the past 30 days. Torchmark Corporation has a market cap of $6.6 billion and is part of the financial sector and insurance industry. Shares are up 39.6% year to date as of the close of trading on Thursday.

Torchmark Corporation, through its subsidiaries, provides various life and health insurance products, and annuities in the United States, Canada, and New Zealand. The company operates in three segments: Life Insurance, Health Insurance, and Annuities. The stock currently has a dividend yield of 0.94%. The company has a P/E ratio of 12.8.

Exclusive Offer: Get the latest Stock Analysis on TMK - FREE

TheStreet Quant Ratings rates Torchmark Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Torchmark Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

LKQ Corporation (LKQ) - FREE Research Report

Quinn John S who is Executive VP and CFO at LKQ Corporation sold 3,798 shares at $33.48 on Oct. 3, 2013. Following this transaction, the Executive VP and CFO owned 268,495 shares meaning that the stake was reduced by 1.39% with the 3,798 share transaction.

The shares most recently traded at $32.64, down $0.84, or 2.59% since the insider transaction. Historical insider transactions for LKQ Corporation go as follows:

  • 12-Week # shares sold: 8,564
  • 24-Week # shares sold: 35,832

The average volume for LKQ Corporation has been 1.2 million shares per day over the past 30 days. LKQ Corporation has a market cap of $9.5 billion and is part of the consumer goods sector and automotive industry. Shares are up 49.81% year to date as of the close of trading on Thursday.

LKQ Corporation, together with its subsidiaries, provides replacement parts, components, and systems needed to repair vehicles, primarily cars and trucks in the United States, the United Kingdom, Canada, Mexico, and Central America. The company has a P/E ratio of 34.4. Currently there are 5 analysts that rate LKQ Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LKQ - FREE

TheStreet Quant Ratings rates LKQ Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, good cash flow from operations, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full LKQ Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Splunk (SPLK) - FREE Research Report

Neustaetter Thomas M who is Director at Splunk sold 1,500 shares at $61.22 on Oct. 3, 2013. Following this transaction, the Director owned 95,603 shares meaning that the stake was reduced by 1.54% with the 1,500 share transaction.

Sommer Steven R who is SVP & Chief Marketing Officer at Splunk sold 6,000 shares at $60.02 on Oct. 3, 2013. Following this transaction, the SVP & Chief Marketing Officer owned 371,905 shares meaning that the stake was reduced by 1.59% with the 6,000 share transaction.

The shares most recently traded at $61.76, up $1.74, or 2.82% since the insider transaction. Historical insider transactions for Splunk go as follows:

  • 4-Week # shares sold: 235,613
  • 12-Week # shares sold: 319,111
  • 24-Week # shares sold: 372,024

The average volume for Splunk has been 1.1 million shares per day over the past 30 days. Splunk has a market cap of $6.4 billion and is part of the technology sector and computer software & services industry. Shares are up 108.03% year to date as of the close of trading on Thursday.

Splunk, Inc. provides software solutions that provide real-time operational intelligence. Currently there are 11 analysts that rate Splunk a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPLK - FREE

TheStreet Quant Ratings rates Splunk as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and feeble growth in its earnings per share. Get the full Splunk Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

LinkedIn (LNKD) - FREE Research Report

Sze David L who is Director at LinkedIn sold 6,250 shares at $248.03 on Oct. 3, 2013. Following this transaction, the Director owned 198,188 shares meaning that the stake was reduced by 3.06% with the 6,250 share transaction.

The shares most recently traded at $244.09, down $3.94, or 1.61% since the insider transaction. Historical insider transactions for LinkedIn go as follows:

  • 4-Week # shares sold: 6,250
  • 12-Week # shares sold: 79,285
  • 24-Week # shares sold: 191,274

The average volume for LinkedIn has been 1.9 million shares per day over the past 30 days. LinkedIn has a market cap of $23.1 billion and is part of the technology sector and internet industry. Shares are up 114.07% year to date as of the close of trading on Thursday.

LinkedIn Corporation operates an online professional network. The company has a P/E ratio of 702.3. Currently there are 17 analysts that rate LinkedIn a buy, no analysts rate it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LNKD - FREE

TheStreet Quant Ratings rates LinkedIn as a sell. The area that we feel has been the company's primary weakness has been its disappointing return on equity. Get the full LinkedIn Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Vertex Pharmaceuticals (VRTX) - FREE Research Report

Arbuckle Stuart A who is EVP\Chief Commercial Officer at Vertex Pharmaceuticals sold 12,417 shares at $76.28 on Oct. 3, 2013. Following this transaction, the EVP\Chief Commercial Officer owned 39,334 shares meaning that the stake was reduced by 23.99% with the 12,417 share transaction.

The shares most recently traded at $77.70, up $1.42, or 1.83% since the insider transaction. Historical insider transactions for Vertex Pharmaceuticals go as follows:

  • 4-Week # shares sold: 8,300
  • 12-Week # shares sold: 25,247
  • 24-Week # shares sold: 122,161

The average volume for Vertex Pharmaceuticals has been 2.2 million shares per day over the past 30 days. Vertex Pharmaceuticals has a market cap of $17.4 billion and is part of the health care sector and drugs industry. Shares are up 77.88% year to date as of the close of trading on Thursday.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Currently there are 12 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRTX - FREE

TheStreet Quant Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Vertex Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Stocks Trade Lower as Optimism Wanes Over China Trade Talks

Stocks Trade Lower as Optimism Wanes Over China Trade Talks

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know